A series of molecular changes are now known to be seen in human pancreatic neoplasia, including the very frequent mutational activation of Kirsten ras oncogene at codon 12, overexpression of the epidermal growth factor receptor, and abnormalities of c-erbB-2 expression. In order to determine whether similar changes can The epidermal growth factor receptor was identified by the monoclonal antibody F4 raised against a synthetic peptide derived from the intracytoplasmic domain (residues 985-996).2 The antibody was used at a concentration of 6 [ig/ml and was detected by a peroxidase conjugated rabbit anti-mouse (1:50 dilution, Dako UK Ltd). The human squamous carcinoma cell line A43 1 was used as a positive control and substitution of primary antibody for phosphate buffered saline was used as a negative control.
There is considerable evidence to support the notion that multiple genetic events are necessary for neoplastic transformation'2 and several complementary molecular abnormalities have been described in human pancreatic cancer. Firstly, the Kirsten ras gene is mutated at codon 12 in up to 90% of cases.3'8 Secondly, the c-erbB-2 proto-oncogene, which is closely related in sequence and structure to the epidermal growth factor receptor,910 is overexpressed in at least 20% of patients." Thirdly, the epidermal growth factor receptor (c-erbB-1) is abnormally expressed in 30 to 50% of pancreatic cancers.'2 13 Finally, there is evidence that the potential ligands for the epidermal growth factor receptor, transforming growth factor a, and epidermal growth factor are expressed by pancreatic tumour cells'4 and thus may form an autocrine loop. 5 16 Several animal models of pancreatic cancer have been described. ' The epidermal growth factor receptor was identified by the monoclonal antibody F4 raised against a synthetic peptide derived from the intracytoplasmic domain (residues 985-996).2 The antibody was used at a concentration of 6 [ig/ml and was detected by a peroxidase conjugated rabbit anti-mouse (1:50 dilution, Dako UK Ltd). The human squamous carcinoma cell line A43 1 was used as a positive control and substitution of primary antibody for phosphate buffered saline was used as a negative control.
The c-erbB-2 proto-oncogene expression was detected by a polyclonal antibody, 21N, produced by immunising a rabbit with a synthetic peptide corresponding to amino acid residues 1243 to 1255 of the C terminus of the human c- 1) . Probes were end labelled with y 32P adenosine triphosphate (106 counts per ml of hybridisation buffer) and hybridisation was performed in 3M tetramethyl ammonium chloride buffer. After washing under stringent conditions (62°C for 30 minutes) the filters were autoradiographed at -70°C against Fuji RX film.
Results
Examination of haematoxylin and eosin stained parallel cryostat sections showed hyperplastic and neoplastic nodules as previously described.1820 At 15 months all animals who had undergone pancreaticobiliary diversion had developed hyperplastic nodules, and by 18 months all animals had developed adenomatous lesions.
IMMUNOHISTOCHEMISTRY
There was no evidence of c-erbB-2 or epidermal growth factor receptor immunoreactivity in pancreaticobiliary diversion treated animals or in transection control rats, although both these antibodies are known to recognise the rat proteins'020 (and Gullick WJ, personal communication).
POLYMERASE CHAIN REACTION AND OLIGONUCLEOTIDE HYBRIDISATION
There was no evidence of mutation at position 12 or 61 (where activating mutations might be expected) in the rat Kirsten ras gene since all samples gave strong signals after hybridisation with the wild type probe (Fig 2) 
